Adaptive Biotechnologies Corp
NASDAQ:ADPT

Watchlist Manager
Adaptive Biotechnologies Corp Logo
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Watchlist
Price: 6.39 USD 6.15%
Market Cap: 943m USD
Have any thoughts about
Adaptive Biotechnologies Corp?
Write Note

Adaptive Biotechnologies Corp
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Adaptive Biotechnologies Corp
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Research & Development
-$98.7m
CAGR 3-Years
12%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Research & Development
-$1.3B
CAGR 3-Years
1%
CAGR 5-Years
-6%
CAGR 10-Years
-8%
Danaher Corp
NYSE:DHR
Research & Development
-$1.4B
CAGR 3-Years
4%
CAGR 5-Years
-8%
CAGR 10-Years
-3%
Mettler-Toledo International Inc
NYSE:MTD
Research & Development
-$185.7m
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
-4%
Agilent Technologies Inc
NYSE:A
Research & Development
-$458m
CAGR 3-Years
-1%
CAGR 5-Years
-3%
CAGR 10-Years
-3%
IQVIA Holdings Inc
NYSE:IQV
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Adaptive Biotechnologies Corp
Glance View

Market Cap
942.9m USD
Industry
Life Sciences Tools & Services

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 858 full-time employees. The company went IPO on 2019-06-27. The firm is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). The company uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. The company also focuses on developing immune-mediated therapies in oncology and other disease areas.

ADPT Intrinsic Value
6.94 USD
Undervaluation 8%
Intrinsic Value
Price

See Also

What is Adaptive Biotechnologies Corp's Research & Development?
Research & Development
-98.7m USD

Based on the financial report for Sep 30, 2024, Adaptive Biotechnologies Corp's Research & Development amounts to -98.7m USD.

What is Adaptive Biotechnologies Corp's Research & Development growth rate?
Research & Development CAGR 5Y
-10%

Over the last year, the Research & Development growth was 11%. The average annual Research & Development growth rates for Adaptive Biotechnologies Corp have been 12% over the past three years , -10% over the past five years .

Back to Top